News
NICE backs Rinvoq for moderate active RA
AbbVie has announced that its oral therapy Rinvoq (upadacitinib) has received a positive recommendation from the National Institute for Health and Care Excellence (NICE) for the treatment of moderate active rheumatoid arthritis (RA).